| Previous close | 53.47 |
| Open | 53.47 |
| Bid | 38.60 |
| Ask | 44.20 |
| Strike | 240.00 |
| Expiry date | 2023-10-20 |
| Day's range | 53.47 - 53.47 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
ZacksIonis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%
Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.
GlobeNewswireBiogen Completes Acquisition of Reata Pharmaceuticals
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transact
ZacksBiogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Biogen Inc. (BIIB) closed at $255.02, marking a -1.03% move from the previous day.
